The present invention relates to a process for the preparation of 3-[[(1S,2S,3R)- 2,3-Difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl]oxy]-5- fluorobenzonitrile compound of formula-1 which is represented by the following structural formula:
C07C 317/22 - SulfonesSulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
C07C 317/14 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
C07C 315/04 - Preparation of sulfonesPreparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
The present disclosure provides a liquid composition of Cyantraniliprole. An aspect of the present disclosure provides a liquid insecticidal composition comprising: (a) Cyantraniliprole in an amount of 0.5-50 wt.% by weight of the composition; (b) at least one other biologically active agent in an amount of 0 -20 wt.% by weight of the composition; (c) bentonite clay in an amount of 0.1-10 10 wt.% by weight of the composition; (d) an anionic surfactant having carboxylate functional groups in an amount of 1-20 wt.% by weight of the composition; (e) a non-ionic surfactant in an amount of 1-50 wt.% by weight of the composition; and (f) a water immiscible liquid carrier in an amount of 20-95 wt.% by weight of the composition. Aspects of the present disclosure also relates to a process for 15 preparation of the liquid insecticidal composition, and a process for controlling arthropod pests.
A01N 37/22 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof the nitrogen atom being directly attached to an aromatic ring system, e.g. anilides
The present invention relates to an improved process for the preparation of Crystalline Form-A of Cyantraniliprole of Formula-I.
The present invention relates to an improved process for the preparation of Crystalline Form-A of Cyantraniliprole of Formula-I.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
4.
AN IMPROVED PROCESS FOR THE PREPARATION OF NIRAPARIB TOSYLATE MONOHYDRATE
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 211/18 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
5.
NOVEL POLYMORPHIC FORMS OF ASCIMINIB AND ITS PHARMACEUTICAL SALTS THEREOF
The present invention relates to an improved process for the preparation of Asciminib comprising novel process intermediates. The invention also described the novel polymorphic forms of Asciminib and its pharmaceutical salts.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
6.
FUNGICIDAL COMPOSITIONS COMPRISING TRIFLOXYSTROBIN AND TEBUCONAZOLE
The present disclosure provides a fungicidal composition comprising trifloxystrobin and tebuconazole. An aspect of the present disclosure provides a fungicidal composition, said composition comprising: (a) trifloxystrobin in an amount ranging from 1 to 50 wt. % by weight of the composition; (b) tebuconazole in an amount ranging from 20 to 90 wt. % by weight of the composition; (c) a modified styrene acrylic polymer in an amount ranging from 0.1 to 25 wt. % by weight of the composition; and (d) an adjuvant. Further aspects of the present disclosure provides a process for preparation of a water dispersible granule (WG) formulation comprising trifloxystrobin and tebuconazole, and a method for treatment of plants.
A01N 37/50 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids the nitrogen atom being doubly bound to the carbon skeleton
The present invention relates to an improved process for the preparation of Ruxolitinib phosphate (1) using novel intermediate compound of Formula (14). The present invention also relates to a process for the preparation of intermediate compound of Formula (14).
The present invention relates to a process for the preparation of 7-chloro-6- fluoro-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]pyrido[2,3-d]pyrimidine-2,4 (1H,3H)-dione (M-Dione), a key intermediate of Sotorasib which is represented by the following structural formula: Formula-2.
C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
The present invention relates to pharmaceutical compositions comprising a Bruton tyrosine kinase (BTK) inhibitor. More particularly, the present invention relates to a composition comprising Acalabrutinib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention relates to an improved process for the preparation of (5S,6S,9R)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b] pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidine carboxylate compound of formula-1 with desfluro impurity at less than 0.1% level and in its crystalline form which is represented by the following structural formula-1.
C07D 221/04 - Ortho- or peri-condensed ring systems
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
12.
AN IMPROVED PROCESS FOR THE PREPARATION OF TRABECTEDIN
The present invention is related to novel process for preparation of Trabectedin which involves less expensive reagents, solvents and the process conditions can be easily adopted for commercial scale.
C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
13.
EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER
The invention relates to the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (preferably recurrent squamous cell carcinoma of the head and neck) with a compound which is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof. The invention also relates to the treatment of head and neck cancer with a compound which is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof, wherein the treating the head and neck cancer comprises reducing the size of one or more tumours associated with the head and neck cancer.
The present disclosure generally relates to the technical field of herbicidal compositions. More particularly, the present disclosure provides a storage stable liquid composition of Pinoxaden. An aspect of the present disclosure provides a liquid herbicidal composition, said composition comprising: (a) Pinoxaden in an amount ranging from 0.5 to 50 % w/w; (b) a built-in adjuvant in an amount ranging from 10 to 40 wt. % w/w, said built-in adjuvant being an alkoxylated polyol ester; and (c) an alcohol in an amount ranging from 0.5 to 20 % w/w. Aspects of the present disclosure also relates to a process for preparation of the liquid herbicidal composition.
A01N 43/00 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
15.
IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES
The present invention describes an improved second generation process for the synthesis of NRC-1111 (1,5-[2-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-7-(4-morpholinyl)thieno[2,3-c] pyridine-5-yl]-2-pyrimidinamine) dimethane sulfonate and NRC-1109 (II, 5-[3-methyl-2-[(4-methylsulfonylpiperazin-1-yl)methyl]-7-morpholino-thieno[2,3-c]pyridin-5-yl]pyrimidin-2-amine) dimethane sulfonate. This process is cost effective, high yielding and industrially feasible process for the synthesis of compounds of formulae I and II with high purity. Formula (I) Formula (I): R═H for NRC-1111 and Formula (II): R═CH3 for NRC-1109 NRC-1111 and NRC-1109 are potential anti-cancer agents.
The invention relates to the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (preferably recurrent squamous cell carcinoma of the head and neck) with a compound which is (3-ethynyl-phenyl)-[7- methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof. The invention also relates to the treatment of head and neck cancer with a compound which is (3-ethynyl-phenyl)-[7-methoxy- 6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof, wherein the treating the head and neck cancer comprises reducing the size of one or more tumours associated with the head and neck cancer.
C07C 237/30 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07C 205/57 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
18.
AN IMPROVED PROCESS FOR THE PREPARATION OF INTERMEDIATE OF CYANTRANILIPROLE
C07C 229/56 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho- position
C07C 237/30 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
C07C 253/14 - Preparation of carboxylic acid nitriles by reaction of cyanides with halogen-containing compounds with replacement of halogen atoms by cyano groups
C07C 255/58 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
19.
AN IMPROVED PROCESS FOR THE PREPARATION OF TUCATINIB AND ITS SALT & POLYMORPHS THEREOF
The present invention relates to an improved process for the preparation of (N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine compound of formula-1 and its salt & polymorphs thereof which is represented by the following structural formula.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to pharmaceutical compositions comprising a Bruton tyrosine kinase (BTK) inhibitor. More particularly, the present invention relates to a composition comprising Acalabrutinib maleate and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
5 The present invention relates to a Co-crystal of Upadacitinib. More particularly, the present invention relates to a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), characterized by powder X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 7.4, 9.7, 10.6, 12.5, 14.3, 15.9, 16.6, 21.3 and 24.8° ± 0.2° 2θ" and process for the 10 preparation thereof. (S)(R)Diacetyl-D-tartaric acid (DATA) Formula-I
The present invention relates to an improved process for the preparation of Risdiplam compound of Formula-I. The present invention also relates to novel intermediates of Risdiplam compound of Formula-I and process for the preparation of the same.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61K 9/00 - Medicinal preparations characterised by special physical form
23.
AN IMPROVED PROCESS FOR THE PREPARATION OF ERDAFITINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS & POLYMORPHS THEREOF
The present invention relates to an improved process for the preparation of N- (3,5dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl) quinoxalin-6-yl]ethane-1,2-diamine compound of formula-1 which is represented by the following structural formula: Formula-1.
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
24.
AN IMPROVED PROCESS FOR THE PREPARATION OF SELUMETINIB SULFATE
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
C07C 227/04 - Formation of amino groups in compounds containing carboxyl groups
C07D 235/06 - BenzimidazolesHydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
The present invention relates to stable pharmaceutical compositions comprising a kinase inhibitor. More particularly, the present invention relates to stable tablet compositions comprising Erdafitinib and one or more pharmaceutically acceptable excipients and processes for preparing such compositions.
The present invention relates to stable pharmaceutical compositions comprising a kinase inhibitor. More particularly, the present invention relates to stable tablet compositions comprising Erdafitinib and one or more pharmaceutically acceptable excipients and processes for preparing such compositions.
The present invention relates to pharmaceutical compositions comprising a kinase inhibitor. More particularly, the present invention relates to immediate release pharmaceutical compositions comprising Ribociclib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention relates to process for the preparation of intermediates of Eribulin and process for the preparation of the same. The process of the present invention involves less expensive reagents, solvents and the process conditions can be easily adopted for commercial scale.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
C07D 307/28 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
29.
AN IMPROVED PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM-A OF CYANTRANILIPROLE
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
30.
AN IMPROVED PROCESS FOR THE PREPARATION OF ANHYDROUS CRYSTALLINE FORM-I OF BOSCALID
The present invention relates to an improved process for the preparation of Ruxolitinib phosphate (1) using novel intermediate compound of Formula (14). The present invention also relates to a process for the preparation of intermediate compound of Formula (14).
The present invention relates to an improved process for the preparation of Ruxolitinib phosphate (1) using novel intermediate compound of Formula (14). The present invention also relates to a process for the preparation of intermediate compound of Formula (14).
The present invention relates to an improved and industrially viable process for the preparation of Acalabrutinib and its Intermediates. The present invention involves less expensive reagents, solvents and the process conditions can be easily adopted for commercial scale. The present invention relates to process for the preparation Acalabrutinib of formula (1) and process for the preparation of Acalabrutinib key starting material.
The present invention relates to an improved and industrially viable process for the preparation of Acalabrutinib and its Intermediates. The present invention involves less expensive reagents, solvents and the process conditions can be easily adopted for commercial scale. The present invention relates to process for the preparation Acalabrutinib of formula (1) and process for the preparation of Acalabrutinib key starting material.
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
35.
AN IMPROVED PROCESS FOR THE PREPARATION OF TRABECTEDIN
The present invention is related to novel process for preparation of Trabectedin which involves less expensive reagents, solvents and the process conditions can be easily adopted for commercial scale.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
C07D 497/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
36.
NOVEL CRYSTALLINE POLYMORPH OF LURBINECTEDIN AND IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN
The present invention provides an improved process for the preparation of (12aR)-3,4,12,12a-tetrahydro-7-(phenylmethoxy)-1H-[1,4]oxazino[3,4-c] pyrido[2,1-f] [1,2,4]triazine-6,8-dione of Formula (I). Formula I which is a key intermediate in the synthesis of Baloxavir Morboxil of Formula (II).
C07C 51/363 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogenPreparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by substitution of halogen atoms by other halogen atoms
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
38.
EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER
The invention relates to the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (preferably recurrent squamous cell carcinoma of the head and neck) with a compound which is (3-ethynyl-phenyl)-[7-methoxy-6-(3- morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof. The invention also relates to the treatment of head and neck cancer with a compound which is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl- propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof, wherein the treating the head and neck cancer comprises reducing the size of one or more tumours associated with the head and neck cancer.
The invention relates to the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (preferably recurrent squamous cell carcinoma of the head and neck) with a compound which is (3-ethynyl-phenyl)-[7-methoxy-6-(3- morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof. The invention also relates to the treatment of head and neck cancer with a compound which is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl- propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof, wherein the treating the head and neck cancer comprises reducing the size of one or more tumours associated with the head and neck cancer.
The present invention describes an improved second generation process for the synthesis of NRC-1111 (1,5-[2-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-7-(4-morpholinyl)thieno[2,3-c] pyridine-5-yl]-2-pyrimidinamine) dimethane sulfonate and NRC-1109 (II, 5-[3-methyl-2-[(4-methylsulfonylpiperazin-1-yl)methyl]-7-morpholino-thieno[2,3-c]pyridin-5-yl]pyrimidin-2-amine) dimethane sulfonate. This process is cost effective, high yielding and industrially feasible process for the synthesis of compounds of formulae I and II with high purity. Formula (I) Formula (I): R = H for NRC-1111 and Formula (II): R = CH3 for NRC-1109 NRC-1111 and NRC-1109 are potential anti-cancer agents.
The present invention describes an improved second generation process for the synthesis of NRC-1111 (1,5-[2-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-7-(4-morpholinyl)thieno[2,3-c] pyridine-5-yl]-2-pyrimidinamine) dimethane sulfonate and NRC-1109 (II, 5-[3-methyl-2-[(4-methylsulfonylpiperazin-1-yl)methyl]-7-morpholino-thieno[2,3-c]pyridin-5-yl]pyrimidin-2-amine) dimethane sulfonate. This process is cost effective, high yielding and industrially feasible process for the synthesis of compounds of formulae I and II with high purity. Formula (I) Formula (I): R = H for NRC-1111 and Formula (II): R = CH3 for NRC-1109 NRC-1111 and NRC-1109 are potential anti-cancer agents.
The present invention relates to a process for the preparation of 4-(4-{[2-(4-chlorophenyl)-4,4dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b] pyridin-5-yloxy)benzamide) compound of formula-1 which is represented by the following structural formula:
The present invention relates to a process for the preparation of 4-(4-{[2-(4-chlorophenyl)-4,4dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b] pyridin-5-yloxy)benzamide) compound of formula-1 which is represented by the following structural formula:
The present invention relates to pharmaceutical compositions comprising a tyrosine kinase inhibitor. More particularly, the present invention relates to a composition comprising Nilotinib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention relates to pharmaceutical compositions comprising a Bruton tyrosine kinase (BTK) inhibitor. More particularly, the present invention relates to a composition comprising Acalabrutinib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention relates to novel crystalline Forms of Tafamidis and process to prepare thereof. The present invention also relates to process of Tafamidis N-methyl-D-glucamine.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
46.
PROCESS FOR THE PREPARATION OF ERIBULIN AND ITS INTERMEDIATES
The present invention relates to a process for the preparation of Eribulin Intermediates. The present invention involves less expensive solvents and the process conditions can be easily adopted for commercial scale.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
47.
PROCESS FOR THE PREPARATION OF HIGH PURE ERIBULIN AND ITS MESYLATE SALT
The present invention relates to a process for the preparation of high pure Eribulin and Eribulin Mesylate. The present invention involves preparation of high pure Eribulin and its mesylate salt involving chiral acid addition salts of Eribulin.
C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
C07C 311/19 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
48.
Process for the preparation of Tipiracil hydrochloride and intermediates thereof
The present invention provides a process for the preparation of Tipiracil HCl of Formula (I) and intermediate thereof with improved yields and purities.
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 207/22 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 239/553 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
The present invention relates to pharmaceutical compositions comprising a kinase inhibitor. More particularly, the present invention relates to immediate release pharmaceutical compositions comprising Ribociclib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention relates to pharmaceutical compositions comprising a kinase inhibitor. More particularly, the present invention relates to immediate release pharmaceutical compositions comprising Ribociclib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention provides an improved process for the preparation of Sugammadex sodium of formula (I) having more than 98.5% purity along with less than 1.0% monohydroxy Sugammadex sodium and less than 0.15% any other known or unknown impurities by HPLC.
The present invention relates to immediate release pharmaceutical compositions comprising a kinase inhibitor. More particularly, the present invention relates to immediate release pharmaceutical compositions comprising Palbociclib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention relates to pharmaceutical compositions comprising Lenalidomide. More particularly, the present invention relates to a stable composition comprising anhydrous Lenalidomide Form I and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
54.
Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof
The present invention relates to an improved process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide compound of formula-1 which is represented by the following structural formula:
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
56.
NOVEL PROCESS FOR THE PREPARATION OF ACALABRUTINIB AND ITS INTERMEDIATES
The present invention relates to an improved and industrially viable process for the preparation of Acalabrutinib and its Intermediates. The present invention involves less expensive reagents, solvents and the process conditions can be easily adopted for commercial scale. The present invention relates to process for the preparation Acalabrutinib of formula (1) and process for the preparation of Acalabrutinib key starting material.
The present invention relates to an improved process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate (1/1) compound of formula-1a and its novel crystalline forms. The said compound of formula-1a is represented by the following structural formula: Formula-1a
The present invention relates to pharmaceutical compositions comprising Ibrutinib. More particularly, the present invention relates to a tablet composition comprising Ibrutinib and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention relates to a process for the preparation of 4-(4-{[2-(4-chlorophenyl)-4,4dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b] pyridin-5-yloxy)benzamide) compound of formula-1 which is represented by the following structural formula: Formula-1.
The present invention relates to pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride. More particularly, the present invention relates to a tablet composition comprising trifluridine, tipiracil hydrochloride and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
Present invention relates to an improved process for the preparation of N—(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride of formula-I.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
63.
Intermediates for the preparation of eribulin thereof
The present invention relates to novel intermediates of Eribulin and process for the preparation of the same. The process of the present invention is commercially viable and can be easily adopted for plant scale operations. The present invention relates to tetrahydrofuran compounds of formula I, X, XI, D and B.
The present invention relates to an improved, high yielding and industrially viable process for the preparation of high pure Lapatinib of formula (1). The present invention involves simple crystallization techniques avoiding column chromatographic techniques and the process conditions can be easily adopted for scale-up studies.
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
65.
AN IMPROVED PROCESS FOR THE PREPARATION OF TIPIRACIL HYDROCHLORIDE AND INTERMEDIATES THEREOF
The present invention provides a process for the preparation of Tipiracil HCl of Formula (I) and intermediate thereof with improved yields and purities.
The present invention relates to a process for the preparation of high pure Eribulin and Eribulin Mesylate. The present invention involves preparation of high pure Eribulin and its mesylate salt involving chiral acid addition salts of Eribulin.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
67.
PROCESS FOR THE PREPARATION OF ECTEINASCIDIN DERIVATIVE AND ITS INTERMEDIATE
The present invention relates to an improved and industrially viable process for the preparation of Trabectedin. The present invention also relates to an improved and industrially viable process for the preparation of Trabectedin Intermediate compound of formula-A. The present invention involves less expensive reagents, solvents and the process conditions can be easily adopted for commercial scale.
C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
68.
Process for the preparation of amorphous idelalisib
The present invention relates to a process for the preparation of stable and 5 pure amorphous form of Idelalisib. Further, the present process is simple, more economical, cost effective and efficient method of manufacturing that is suitable for industrial scale-up having a high degree of chromatographic purity.
The present invention provides an improved process for the preparation of Sugammadex sodium of formula (I) having more than 98.5% purity along with less than 1.0% monohydroxy Sugammadex sodium and less than 0.15% any other known or unknown impurities by HPLC.
The invention relates to pharmaceutical compositions of pomalidomide comprising pomalidomide and binder or filler at amount of at most 89% weight percent of total weight of the composition and process for the preparation of such compositions.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
71.
AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention relates to an improved process for the preparation of anthranilamide derivatives. More particularly, the present invention relates to an improved process for the preparation of Chlorantraniliprole-(Ia) and Cyantraniliprole-(Ib).
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
73.
Process for the preparation of dasatinib polymorph
The present invention is related to an improved process for the preparation of dasatinib anhydrous crystalline Neat form N-6 with high purity and high yield. The present invention also relates to purification of dasatinib crystalline Neat form N-6.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to pharmaceutical compositions comprising sacubitril-valsartan complex. More particularly, the present invention relates to a stable composition comprising trisodium salt of sacubitril-valsartan complex trihydrate and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
The present invention relates to pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride. More particularly, the present invention relates to a tablet composition comprising trifluridine, tipiracil hydrochloride and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention relates to a process for the preparation of sorafenib tosylate form III from sorafenib base through sorafenib tosylate methanol solvate. The present invention relates to an improved process for the preparation of Sorafenib tosylate form III with high purity and high yield. The present process controls the genotoxic impurities content in final API.
The present invention relates to an improved process for the preparation of Ibrutinib with high purity and high yields. The present process is cost effective and feasible in large scale production also. The present process avoids the mitsunobu reagent conditions also. The present Invention also relates to a process for the preparation of Crystalline form A and Crystalline form C of Ibrutinib.
C07D 473/04 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
78.
Process for the preparation of pomalidomide and its purification
The present invention is related to an improved process for the preparation of Pomalidomide with higher yields and high purity. Particularly the present invention relates to form A preparation of Pomalidomide and its purification. wherein the present process doesn't involve use of dioxane solvent and avoids higher temperatures.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
79.
AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB SUCCINATE AND ITS NOVEL CRYSTALLINE FORMS THEREOF
The present invention relates to an improved process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate (1/1) compound of formula-1a and its novel crystalline forms. The said compound of formula-1a is represented by the following structural formula:. Formula-1a
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to pharmaceutical compositions comprising Ibrutinib. More particularly, the present invention relates to a tablet composition comprising Ibrutinib and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention relates to pharmaceutical compositions comprising Ibrutinib. More particularly, the present invention relates to a tablet composition comprising Ibrutinib and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention relates to pharmaceutical compositions comprising Lenalidomide. More particularly, the present invention relates to a stable composition comprising anhydrous Lenalidomide Form I and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
83.
INTERMEDIATES FOR THE PREPARATION OF ERIBULIN THEREOF
The present invention relates to novel intermediates of Eribulin and process for the preparation of the same. The process of the present invention is commercially viable and can be easily adopted for plant scale operations. The present invention relates to tetrahydrofuran compounds of formula I, X, XI, D and B.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
84.
AN IMPROVED PROCESS FOR THE PREPARATION OF ELBASVIR AND ITS SALT THEREOF
The present invention provides a novel process for the preparation of 2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid of Formula (I), (I) which is a key intermediate in the synthesis of Alectinib or its salt of Formula (II).
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
86.
Modified process for the preparation of Ceritinib and amorphous form of Ceritinib
The present invention is related to an improved process for the preparation of Ceritinib with high yield and high purity. The present process is cost effective and feasible in large scale production also. The present invention also related to a stable amorphous form of Ceritinib and its preparation. The present invention also relates to a process for the preparation of Crystalline form A of Ceritinib.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The invention relates to oral pharmaceutical compositions comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1:1 in the form of solid dispersion and process for the preparation of such compositions.
The invention relates to oral pharmaceutical compositions of dabigatran or a pharmaceutically acceptable salts thereof and process for the preparation of such compositions.
A61K 9/60 - Organic coatings containing natural gums or resins
A61K 31/00 - Medicinal preparations containing organic active ingredients
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
89.
PROCESS FOR THE PREPARATION OF AMORPHOUS IDELALISIB
The present invention relates to a process for the preparation of stable and 5 pure amorphous form of Idelalisib. Further, the present process is simple, more economical, cost effective and efficient method of manufacturing that is suitable for industrial scale-up having a high degree of chromatographic purity.
Present invention relates to an improved process for the preparation of N-(3- ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride of formula-I.
Present invention relates to an improved process for the preparation of N-(3- ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride of formula-I.
The present invention relates to improved process for the production of Pirfenidone which is comprises reacting the compound of 5-methyl-2(1H)-pyridone of formula (III) with bromobenzene (IV) in polar solvent, in presence of base and activated Cu powder to obtain the compound of formula (I). The present invention is also related to purification of Pirfenidone.
The invention relates to pharmaceutical compositions of pomalidomide comprising pomalidomide and binder or filler at amount of at most 89% weight percent of total weight of the composition and process for the preparation of such compositions.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
95.
AN IMPROVED PROCESS FOR THE PREPARATION OF DASATINIB POLYMORPH
The present invention is related to an improved process for the preparation of dasatinib anhydrous crystalline Neat form N-6 with high purity and high yield. The present invention also relates to purification of dasatinib crystalline Neat form N-6.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
96.
PROCESS FOR THE PREPARATION OF AMORPHOUS FORM OF CANAGLIFLOZIN
The present invention relates to an improved process for the preparation of amorphous form of Canagliflozin with high purity and high yield. Particularly the present invention is related to the direct isolation of amorphous form of Canagliflozin from reaction mixture and also related to purification of amorphous form of Canagliflozin through piperidine-4-carboxylic acid complex of Canagliflozin.
C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
97.
PROCESS FOR THE PREPARATION OF POMALIDOMIDE AND ITS PURIFICATION
The present invention is related to an improved process for the preparation of Pomalidomide with higher yields and high purity. Particularly the present invention relates to form A preparation of Pomalidomide and its purification. wherein the present process doesn't involve use of dioxane solvent and avoids higher temperatures.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
98.
7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs
The present invention relates to novel series of substituted 7-(morpholinyl)-2-(N-piperazinyl)-methyl thieno [2, 3-c] pyridines of the following structure of formula I. Where in R1, R2, R3 and R4 are defined.
The present invention is related to an improved process for the preparation of ceritinib with high yield and high purity. The present process is cost effective and feasible in large scale production also. The present invention also related to a stable amorphous form of ceritinib and its preparation. The present invention also relates to a process for the preparation of Crystalline form A of Ceritinib.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to an improved process for the preparation of Ibrutinib with high purity and high yields. The present process is cost effective and feasible in large scale production also. The present process avoids the mitsunobu reagent conditions also. The present Invention also relates to a process for the preparation of Crystalline form A and Crystalline form C of Ibrutinib.
C07D 473/04 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
patents
